nasty^PhysIc
Competitive Bodybuilder
- Lid sinds
- 12 feb 2004
- Berichten
- 2.498
- Waardering
- 0
Anavar ( oxandrolone ) is veilig??
- Topic starter nasty^PhysIc
- Startdatum
- Recente activiteit Recente activiteit:
- Reacties 6
- Weergaven 1.271
- Volgers 0
-
- Tags
- anavar oxandrolone
- Lid sinds
- 10 mrt 2003
- Berichten
- 5.504
- Waardering
- 5
nasty^PhysIc
Competitive Bodybuilder
- Lid sinds
- 12 feb 2004
- Berichten
- 2.498
- Waardering
- 0
- Lid sinds
- 10 mrt 2003
- Berichten
- 5.504
- Waardering
- 5
nasty^PhysIc zei:
De doseringen die men door artsen voorgeschreven krijgt verschillen nogal met wat de gemiddelde bodybuilder gebruikt. Een tijdje dacht men inderdaad dat anavar heel veilig was, nu weet men dat er toch grotere risico's aan vast zitten dan aanvankelijk gedacht. Het is echter wel zo dat het een relatief veilig middel is.
eddycaminos
Advanced Bodybuilder
- Lid sinds
- 30 mei 2003
- Berichten
- 1.147
- Waardering
- 1
- Lid sinds
- 7 jan 2004
- Berichten
- 9.350
- Waardering
- 2
nasty^PhysIc zei:
Vraag maar aan Richard Sandrak....die zou het moeten weten
Unregistered
Advanced Bodybuilder
- Lid sinds
- 19 aug 2003
- Berichten
- 1.339
- Waardering
- 2
A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy.
Fenichel GM, Griggs RC, Kissel J, Kramer TI, Mendell JR, Moxley RT, Pestronk A, Sheng K, Florence J, King WM, Pandya S, Robison VD, Wang H.
Department of Neurology, Ohio State University College of Medicine, USA. gerald.fenichel@mcmail.vanderbilt.edu
BACKGROUND: A pilot study suggested that oxandrolone, an anabolic steroid, improved strength in boys with Duchenne dystrophy (DD) and indicated the need for a more definitive study. METHODS: A 6-month, randomized, double-blind, placebo-controlled study of oxandrolone in boys with an established diagnosis of DD, using the change from baseline to 6 months in the average muscle strength score (MMT) as the primary efficacy measure. RESULTS: The mean change from baseline for the oxandrolone group was +0.035 and that for the placebo group was -0.140. Although the oxandrolone group did not get worse and the placebo patients showed some deterioration in strength, the difference was not significant (p = 0.13). The average of the four quantitative muscle tests (QMT) showed a significant improvement in the oxandrolone-treated boys as compared with placebo. No adverse reactions attributable to oxandrolone were recorded. CONCLUSIONS: Although oxandrolone did not produce a significant change in the average manual muscle strength score as compared with placebo, the mean change in QMT was significant. Because oxandrolone is safe, accelerates linear growth, and may have some beneficial effect in slowing the progress of weakness, it may be useful before initiating corticosteroid therapy.
Publication Types:
Clinical Trial
Multicenter Study
Randomized Controlled Trial
PMID: 11320181 [PubMed - indexed for MEDLINE]
A beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: a pilot study.
Fenichel G, Pestronk A, Florence J, Robison V, Hemelt V.
Department of Neurology, Vanderbilt University School of Medicine, Nashville, TN 37212, USA.
We treated 10 boys with Duchenne muscular dystrophy with oxandrolone, an anabolic steroid, for 3 months. The mean of the changes in the average muscle score was an improvement of 0.315 +/- 0.097. The expected mean change in muscle score after 3 months from natural history data is a loss of 0.1. The difference of 0.415 between the actual and expected values is significant at p < 0.01. This preliminary evidence suggests that oxandrolone treatment may provide a degree of functional benefit for children with Duchenne muscular dystrophy that is similar to that after prednisone administration.
PMID: 9153447 [PubMed - indexed for MEDLINE]
Staan geen doseringen bij
Fenichel GM, Griggs RC, Kissel J, Kramer TI, Mendell JR, Moxley RT, Pestronk A, Sheng K, Florence J, King WM, Pandya S, Robison VD, Wang H.
Department of Neurology, Ohio State University College of Medicine, USA. gerald.fenichel@mcmail.vanderbilt.edu
BACKGROUND: A pilot study suggested that oxandrolone, an anabolic steroid, improved strength in boys with Duchenne dystrophy (DD) and indicated the need for a more definitive study. METHODS: A 6-month, randomized, double-blind, placebo-controlled study of oxandrolone in boys with an established diagnosis of DD, using the change from baseline to 6 months in the average muscle strength score (MMT) as the primary efficacy measure. RESULTS: The mean change from baseline for the oxandrolone group was +0.035 and that for the placebo group was -0.140. Although the oxandrolone group did not get worse and the placebo patients showed some deterioration in strength, the difference was not significant (p = 0.13). The average of the four quantitative muscle tests (QMT) showed a significant improvement in the oxandrolone-treated boys as compared with placebo. No adverse reactions attributable to oxandrolone were recorded. CONCLUSIONS: Although oxandrolone did not produce a significant change in the average manual muscle strength score as compared with placebo, the mean change in QMT was significant. Because oxandrolone is safe, accelerates linear growth, and may have some beneficial effect in slowing the progress of weakness, it may be useful before initiating corticosteroid therapy.
Publication Types:
Clinical Trial
Multicenter Study
Randomized Controlled Trial
PMID: 11320181 [PubMed - indexed for MEDLINE]
A beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: a pilot study.
Fenichel G, Pestronk A, Florence J, Robison V, Hemelt V.
Department of Neurology, Vanderbilt University School of Medicine, Nashville, TN 37212, USA.
We treated 10 boys with Duchenne muscular dystrophy with oxandrolone, an anabolic steroid, for 3 months. The mean of the changes in the average muscle score was an improvement of 0.315 +/- 0.097. The expected mean change in muscle score after 3 months from natural history data is a loss of 0.1. The difference of 0.415 between the actual and expected values is significant at p < 0.01. This preliminary evidence suggests that oxandrolone treatment may provide a degree of functional benefit for children with Duchenne muscular dystrophy that is similar to that after prednisone administration.
PMID: 9153447 [PubMed - indexed for MEDLINE]
Staan geen doseringen bij
